Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting
December 07, 2022 07:00 ET
|
Axsome Therapeutics, Inc.
Improvement in cognitive and physical functioning, measured by the CPFQ patient-rated scale, starting at week 1 and sustained over 12 months Improvement in disability, measured by the SDS, starting...
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation
November 28, 2022 06:35 ET
|
Axsome Therapeutics, Inc.
AXS-05 statistically significantly delayed time to relapse of Alzheimer’s disease agitation versus placebo (p=0.014, primary endpoint) AXS-05 statistically significantly prevented relapse of...
Axsome Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference
November 23, 2022 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics to Present at the Guggenheim 4th Annual Immunology and Neurology Conference
November 09, 2022 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
November 07, 2022 07:00 ET
|
Axsome Therapeutics, Inc.
Sunosi® third quarter U.S. net sales of $16.8 million Auvelity™ launched and available in U.S. pharmacies SHARP study results announced demonstrating statistically significant improvement in...
Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today
October 27, 2022 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics to Report Third Quarter 2022 Financial Results on November 7, 2022
October 21, 2022 07:00 ET
|
Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Monday, November 7, 2022 at 8:00 AM Eastern Time NEW YORK, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
Axsome Therapeutics Announces Availability of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults
October 20, 2022 07:00 ET
|
Axsome Therapeutics, Inc.
AUVELITY is the first and only rapid-acting oral treatment approved with labeling of statistically significant improvement in depressive symptoms compared to placebo starting at one week1-4 ...
Axsome Therapeutics Voices its Commitment to Mental Health on World Mental Health Day 2022
October 10, 2022 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics Announces Sunosi® (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the SHARP Trial in Cognitively Impaired Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea
October 03, 2022 06:30 ET
|
Axsome Therapeutics, Inc.
Statistically significant improvement in cognitive function, as measured by the DSST RBANS compared to placebo (p=0.009, primary endpoint) Statistically significant patient-reported improvement in...